Plerixafor

@article{DiPersio2009Plerixafor,
  title={Plerixafor},
  author={John F. DiPersio and G L Uy and Uma Yasothan and Peter Kirkpatrick},
  journal={Nature Reviews Drug Discovery},
  year={2009},
  volume={8},
  pages={105-107}
}
In December 2008, plerixafor (Mozobil; Genzyme), an antagonist of the CXCR4 chemokine receptor, was approved by the US FDA for use in combination with granulocyte colony-stimulating factor to mobilize haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.